TRANS'ITION: Evaluation of the Variation in Quality of Life During Medical Transition for Transgender People.

Sponsor
University Hospital, Lille (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05273112
Collaborator
(none)
400
13
84
30.8
0.4

Study Details

Study Description

Brief Summary

Transgender people can benefit from psychological, psychiatric, endocrinological support, sexual reassignment surgery, sexology support and dermatological care. The value of transitional care courses is scientifically recognized. Currently, the modalities of decision and realization of the care paths are heterogeneous on the territory, little standardized, and are the subject of debates between representatives of users and medical teams.

The french national report of IGAS from 2011 warns of the need to argue and legitimize care practices through more numerous, more exhaustive scientific studies, presenting a better level of evidence

Since 2011, no prospective study has been carried out on the national and international level, making it possible to assess the relevance of the planned care modalities. This research project, conducted over five consecutive years at the first contact of a transgender people with a care device, aims to correlate a variation in the quality of life of people with the characteristics of the care methods provided. This is a first proposal to assess care practices for transgender people. The results of this study would first allow us to infer the care modalities most suited to the needs of people. Secondly, secondary hypotheses could support new experimental protocols.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    This research is a prospective multicenter cohort study with a 3-year and 5-year follow-up of transgender people in medical transition.

    Main aim:

    Evaluate the evolution of the quality of life during five years in transgender people who benefit from transition support cares.

    Secondary objectives:
    Secondary objective n°1 :

    Identify the different factors that influence the evolution of quality of life evaluated over three years in transgender people who benefit from transition support cares.

    Secondary objective n°2 :

    Evaluate the evolution of the satisfaction of the shared medical decision for transgender people in medical transition.

    Secondary objective n°3 :

    Evaluate the evolution of the satisfaction of body image for transgender people in medical transition.

    Secondary objective n°4 :

    Evaluate the evolution of psychiatric comorbidities for transgender people in medical transition.

    Secondary objective n°5 :

    Evaluate the benefits and limits in long term (five years) on the quality of life, the satisfaction of the shared medical decision, the satisfaction of body image and the evolution of psychiatric comorbidities.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    400 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Evaluation of the Variation in Quality of Life During Medical Transition According Different Modalities of Supported Care for Transgender People.
    Anticipated Study Start Date :
    Apr 1, 2022
    Anticipated Primary Completion Date :
    Apr 1, 2029
    Anticipated Study Completion Date :
    Apr 1, 2029

    Outcome Measures

    Primary Outcome Measures

    1. Quality of life scores [3 years]

      Scores on the WHOQOL BREF (World Health Organisation Quality Of Life) scale

    Secondary Outcome Measures

    1. Social factors (age, gender, profession, knowledge of care system) [Baseline and 6 months, 12 months, 18 months, 24 months, 30 months, 3 years and 5 years]

      Answers given by the patient during interview

    2. Satisfaction of the shared medical decision [6 months, 12 months, 18 months, 24 months, 30 months, 3 years and 5 years]

      Scores on the CDIS (Clinical Decision-making Involvement and Satisfaction) clinical decision making involvement and satisfaction score 15 questions scored 1-5 (totally disagree, strongly disagree, neither agree nor disagree, strongly agree, totally agree)

    3. Satisfaction of body image [6 months, 12 months, 18 months, 24 months, 30 months, 3 years and 5 years]

      Score on the BIS (Body Image Scale), total score ranges from 0 to 30, A higher score means a higher level of body image disturbance

    4. General psychopathology [6 months, 12 months, 18 months, 24 months, 30 months, 3 years and 5 years]

      French version of Mini International Neuropsychiatric Interview (DSM)

    5. Anxiety and depression [6 months, 12 months, 18 months, 24 months, 30 months, 3 years and 5 years]

      Anxiety and depression scores on the HAD scale (Hospital Anxiety and Depression scale), a score upper 8 means is considered as a risk of an anxiety or depressive disorder

    6. Quality of life scores [6 months, 12 months, 18 months, 24 months, 30 months, 5 years]

      Scores on the WHOQOL BREF (World Health Organisation Quality Of Life) scale

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 75 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • With a diagnosis of Gender Dysphoria according to DSM5 diagnostic criteria

    • Wishing to benefit from supportive care for their transition trajectory and addressing a care system represented by the collaborating centers participating in the study,

    • Willing to comply with all study procedures and duration,

    • Understanding and able to speak French.

    Exclusion Criteria:
    • Minor or adult under curatorship, under judicial protection, persons deprived of their liberty

    • Refusal to participate after clear and fair information from the study

    • Person with sexual reassignment surgery or with cross hormon therapy since two years.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 CHU de Bordeaux Bordeaux France
    2 CHU de Brest Brest France
    3 Centre Hospitalier de Béziers Béziers France
    4 CHU de Caen Caen France
    5 CHU de Lille Lille France
    6 Maison de Santé Lille Moulins Lille France
    7 Maison de Santé Lille Sud Lille France
    8 CHU de Lyon Lyon France
    9 G..R.E.T.T.I.S Lyon France
    10 Hopital de la Conception - Marseille Marseille France
    11 CHU de Nice Nice France
    12 Centre Hospitalier Maison Blanche Paris France
    13 Centre Hospitalier Sainte-Anne Paris France

    Sponsors and Collaborators

    • University Hospital, Lille

    Investigators

    • Principal Investigator: François MEDJKANE, MD, University Hospital, Lille

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University Hospital, Lille
    ClinicalTrials.gov Identifier:
    NCT05273112
    Other Study ID Numbers:
    • 2020_09
    • 2021-A00154-37
    First Posted:
    Mar 10, 2022
    Last Update Posted:
    Mar 10, 2022
    Last Verified:
    Feb 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by University Hospital, Lille
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 10, 2022